These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 12485956

  • 21. Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers.
    Heinig R, Böttcher MF.
    Clin Drug Investig; 2005; 25(2):115-23. PubMed ID: 17523761
    [Abstract] [Full Text] [Related]

  • 22. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.
    Mao ZL, Alak A, Wheeler JJ, Keirns J.
    Drug Metab Lett; 2011 Apr; 5(2):114-25. PubMed ID: 21457140
    [Abstract] [Full Text] [Related]

  • 23. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
    Kuhlmann JB, Wensing G, Kuhlmann J.
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
    [Abstract] [Full Text] [Related]

  • 24. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
    Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, Ahlner J, Baumann P, Dahl ML.
    Clin Pharmacokinet; 2009 Feb; 48(1):63-70. PubMed ID: 19071885
    [Abstract] [Full Text] [Related]

  • 25. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ.
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
    Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, Brockmöller J.
    Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic profile of fesoterodine.
    Malhotra B, Guan Z, Wood N, Gandelman K.
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):556-63. PubMed ID: 19000553
    [Abstract] [Full Text] [Related]

  • 28. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK, Brøsen K, Hansen MG, Gram LF.
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [Abstract] [Full Text] [Related]

  • 29. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA.
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [Abstract] [Full Text] [Related]

  • 30. Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.
    Yamamoto T, Furihata K, Hisaka A, Moritoyo T, Ogoe K, Kusayama S, Motohashi K, Mori A, Iwatsubo T, Suzuki H.
    J Clin Pharmacol; 2017 Nov; 57(11):1491-1499. PubMed ID: 28679023
    [Abstract] [Full Text] [Related]

  • 31. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
    Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH.
    Br J Clin Pharmacol; 2008 Apr; 65(4):558-64. PubMed ID: 18070221
    [Abstract] [Full Text] [Related]

  • 32. Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.
    Vieira CP, Neves DV, Coelho EB, Lanchote VL.
    Drug Metab Lett; 2018 Apr; 12(1):68-70. PubMed ID: 29676238
    [Abstract] [Full Text] [Related]

  • 33. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K, Awad M, Kamel A.
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [Abstract] [Full Text] [Related]

  • 34. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
    Puozzo C, Lens S, Reh C, Michaelis K, Rosillon D, Deroubaix X, Deprez D.
    Clin Pharmacokinet; 2005 Jun; 44(9):977-88. PubMed ID: 16122284
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects.
    Prakash C, Fan B, Altaf S, Agresta S, Liu H, Yang H.
    Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
    [Abstract] [Full Text] [Related]

  • 37. Association between cytochrome P450 2D6 genotype and harm avoidance.
    Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA.
    Am J Med Genet B Neuropsychiatr Genet; 2004 May 15; 127B(1):90-3. PubMed ID: 15108188
    [Abstract] [Full Text] [Related]

  • 38. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
    Steuer AE, Schmidhauser C, Tingelhoff EH, Schmid Y, Rickli A, Kraemer T, Liechti ME.
    PLoS One; 2016 May 15; 11(3):e0150955. PubMed ID: 26967321
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H, Hansen TS, Brøsen K.
    Pharmacogenetics; 1996 Dec 15; 6(6):513-9. PubMed ID: 9014200
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.